Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIMID
2022-502968-20-02Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of filgotinib in Behçet's disease (BD), Autoimmune Myopathies, dermatomyositis (DM) and 3 more (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: EuroQol 5D-5L (EQ-5D-5L), Behçet’s Disease Current Activity Form (BDCAF) and 1 more. Planned start Dec 2023; status: authorised.
02
Drugs
filgotinib
03
Conditions
Behçet's disease (BD)Autoimmune Myopathiesdermatomyositis (DM)antisynthetase syndrome (ASSD)Overlap Myositis (OM)
Beyond the preview
Go deeper on 2022-502968-20-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502968-20-02.